Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma
Journal of Medical Imaging and Radiation Oncology · 2025
DOI: 10.1111/1754-9485.13794 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Medical Imaging and Radiation Oncology, 2025. Verfasst von Youngju Song und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Radiosurgery, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Introduction
We investigated the clinical outcomes of stereotactic body radiation therapy (SBRT) alone versus SBRT after incomplete transarterial chemoembolization (TACE) for a single recurrent hepatocellular carcinoma (HCC) smaller than 5 cm.
Methods
We retrospectively reviewed the medical records of patients who underwent SBRT for a single recurrent HCC ≤5 cm, without vascular invasion or extrahepatic metastasis. Patients were divided into the SBRT‐alone group and the TACE‐SBRT group. The primary outcome was the local control (LC) rate, and secondary outcomes were survivals and treatment‐related toxicities. We additionally conducted a propensity score matching (PSM) analysis.
Results
A total of 477 patients were available for analysis. Among them, 54 patients received SBRT without prior treatment to the target lesion (SBRT‐alone group), whereas 423 patients received SBRT for viable HCC after TACE (TACE‐SBRT group). The 3‐year LC rates did not differ between the two groups (SBRT‐alone group, 88.6% vs. TACE‐SBRT group, 89.6%, P = 0.918). The 3‐year rates of overall survival, out‐of‐field intrahepatic recurrence‐free survival and recurrence‐free survival were also not significantly different ( P = 0.479, 0.290 and 0.273, respectively). Even after PSM, LC and survival rates at 3 years were not significantly different.
Conclusion
SBRT alone demonstrated comparable local control and survival outcomes to SBRT following incomplete TACE. SBRT alone may be considered an alternative treatment option for a single recurrent HCC smaller than 5 cm when curative treatments or TACE are not feasible.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Radiology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
- Department of Gastroenterology, Asan Liver Center, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
ORCID-Profile: Jinhong Jung
Förderung
- National Research Foundation of Korea
Zitieren
APA
Song, Y., Jung, J., Park, J. H., Kim, S. Y., Choi, J., Lee, D., Shim, J. H., Kim, K. M., Lim, Y. S., Lee, H. C., & Yoon, S. M. (2025). Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma. Journal of Medical Imaging and Radiation Oncology. https://doi.org/10.1111/1754-9485.13794
Vancouver
Song Y, Jung J, Park JH, Kim SY, Choi J, Lee D, et al. Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma. Journal of Medical Imaging and Radiation Oncology. 2025. doi:10.1111/1754-9485.13794
BibTeX
@article{Song2025,
author = {Song, Youngju and Jung, Jinhong and Park, Jin-Hong and Kim, So Yeon and Choi, Jonggi and Lee, Danbi and Shim, Ju Hyun and Kim, Kang Mo and Lim, Young-Suk and Lee, Han Chu and Yoon, Sang Min},
title = {Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma},
journal = {Journal of Medical Imaging and Radiation Oncology},
year = {2025},
doi = {10.1111/1754-9485.13794}
}
EUVIMED